(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2012 (05.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/092612 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/02* (2006.01)

(21) International Application Number:
PCT/US2011/068235

(22) International Filing Date:
30 December 2011 (30.12.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/428,699	30 December 2010 (30.12.2010)	US
61/470,406	31 March 2011 (31.03.2011)	US
61/470,382	31 March 2011 (31.03.2011)	US
61/485,104	11 May 2011 (11.05.2011)	US

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ELIAS, Kathleen Ann** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **LANDES, Gregory** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **SINGH, Shweta** [GB/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **KORVER, Wouter** [NL/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **DRAKE, Andrew Walling** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **HAAK-FRENDSCHO, Mary** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **SNELL, Gyorgy Pal** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US). **BHASKAR, Vinay** [US/US]; C/o Takeda San Francisco, Inc., 285 East Grand Avenue, South San Francisco, CA 94080 (US).

(74) Agents: **SILVA, Robin M.** et al.; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,

[Continued on next page]

(54) Title: ANTI-CD38 ANTIBODIES

FIGURE 11



(57) Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

WO 2012/092612 A1

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*